Thakur Simran, Kumar Vishal, Das Rina, Sharma Vishal, Mehta Dinesh Kumar
Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India.
Department of Pharmaceutical Chemistry, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India.
Curr Ther Res Clin Exp. 2024 Apr 26;100:100737. doi: 10.1016/j.curtheres.2024.100737. eCollection 2024.
Hepatotoxicity is the foremost issue for clinicians and the primary reason for pharmaceutical product recalls. A biomarker is a measurable and quantifiable attribute used to evaluate the efficacy of a treatment or to diagnose a disease. There are various biomarkers which are used for the detection of liver disease and the intent of liver damage.
This review aims to investigate the current state of hepatotoxicity biomarkers and their utility in clinical settings. Using hepatic biomarkers, the presence of liver injury, its severity, prognosis, causative agent, and type of hepatotoxicity can all be determined.
Relevant published articles up to 2022 were systematically retrieved from MEDLINE/PubMed, SCOPUS, EMBASE, and WOS databases using keywords such as and
In clinical trials and everyday practice, biomarkers of drug-induced liver injury are essential for spotting the most severe cases of hepatotoxicity. Hence, developing novel biomarker approaches to enhance hepatotoxicity diagnosis will increase specificity and/or identify the person at risk. Importantly, early clinical studies on patients with liver illness have proved that some biomarkers such as aminotransferase, bilirubin, albumin, and bile acids are even therapeutically beneficial.
By assessing the unique signs of liver injury, health care professionals can rapidly and accurately detect liver damage and evaluate its severity. These measures contribute to ensuring prompt and effective medical intervention, hence reducing the risk of long-term liver damage and other major health concerns.
肝毒性是临床医生面临的首要问题，也是药品召回的主要原因。生物标志物是一种可测量和量化的指标，用于评估治疗效果或诊断疾病。有多种生物标志物可用于检测肝脏疾病和肝损伤情况。
本综述旨在探讨肝毒性生物标志物的现状及其在临床环境中的应用。通过肝脏生物标志物，可以确定肝损伤的存在、严重程度、预后、致病因素以及肝毒性类型。
使用诸如……等关键词，从MEDLINE/PubMed、SCOPUS、EMBASE和WOS数据库中系统检索截至2022年的相关已发表文章。
在临床试验和日常实践中，药物性肝损伤的生物标志物对于发现最严重的肝毒性病例至关重要。因此，开发新的生物标志物方法以加强肝毒性诊断将提高特异性和/或识别高危人群。重要的是，对肝病患者的早期临床研究已证明，一些生物标志物如转氨酶、胆红素、白蛋白和胆汁酸甚至具有治疗益处。
通过评估肝损伤的独特迹象，医护人员可以快速准确地检测肝损伤并评估其严重程度。这些措施有助于确保及时有效的医疗干预，从而降低长期肝损伤和其他重大健康问题的风险。
